A Phase II Study of Oral Rigosertib in Patients with Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma

Trial Profile

A Phase II Study of Oral Rigosertib in Patients with Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Anal cancer; Cervical cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Penile cancer; Skin cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Onconova Therapeutics
  • Most Recent Events

    • 15 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 30 Sep 2015 Planned End Date changed from 1 Sep 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov.
    • 05 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top